Clinical Trial Update: Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions [Phase 1]

View source ↗

Summary

Phase 1 BE and dose proportionality study evaluating test griseofulvin 500 mg tablets vs reference under fed conditions; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antifungal Treatment
• Fungal Infections

Drugs mentioned

• Griseofulvin (GRISEOFULVIN)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Antifungal Agents | Phase 1 | Status: COMPLETED | Results posted: 2020-12-28